A Multicenter Retrospective Comparison of Sequential versus Sandwich Chemoradiotherapy for Stage IE-IIE Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type

Li, Jin; Li, Yajun; Zhong, Meizuo; Liu, Wei; Liu, Xianling; Li, Jiwei; Li, Kunlun; Yi, Ping

doi:10.7150/jca.24310

Cited by 12 publications

(10 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Most data we cite for therapy of advanced NKTL are from retrospective or uncontrolled studies and report similar outcomes with synchronous and metachronous therapy and with diverse radiation therapy and chemotherapy regimens, formats, schedules etc [ 54 , 85 , 86 ]. There are also a myriad of radiation therapy doses, fields, and schedules.…”

Section: What Is the Best Therapy Of Advanced Nktl?mentioning

confidence: 99%

NK-/T-cell lymphomas

Wang

Gale

et al. 2021

Leukemia

View full text Add to dashboard Cite

Natural killer/T-cell lymphoma (NKTL) is a sub-type of Epstein–Barr virus (EBV)-related non-Hodgkin lymphomas common in Asia and Latin America but rare elsewhere. Its pathogenesis is complex and incompletely understood. Lymphoma cells are transformed from NK- or T-cells, sometimes both. EBV-infection and subsequent genetic alterations in infected cells are central to NKTL development. Hemophagocytic syndrome is a common complication. Accurate staging is important to predict outcomes but there is controversy which system is best. More than two-thirds of NKTL lympohmas are localized at diagnosis, are frequently treated with radiation therapy only and have 5-year survival of about 70 percent. Persons with advanced NKTLs receive radiation therapy synchronously or metachronously with diverse multi-drug chemotherapy typically including l-asparginase with 5-year survival of about 40 percent. Some persons with widespread NKTL receive chemotherapy only. There are few data on safety and efficacy of high-dose therapy and a haematopoietic cell autotransplant. Immune therapies, histone deacetylase (HDAC)-inhibitors and other drugs are in early clinical trials. There are few randomized controlled clinical trials in NKTLs and no therapy strategy is clearly best; more effective therapy(ies) are needed. Some consensus recommendations are not convincingly evidence-based. Mechanisms of multi-drug resistance are considered. We discuss these issues including recent advances in our understanding of and therapy of NKTLs.

show abstract

Section: What Is the Best Therapy Of Advanced Nktl?mentioning

confidence: 99%

NK-/T-cell lymphomas

Wang

Gale

et al. 2021

Leukemia

View full text Add to dashboard Cite

show abstract

“…Unfortunately, many patients develop long-term adverse events associated with CCRT, especially on oral and nasal mucosa, which can substantially reduce patients’ quality of life [53] (Table 2). Sandwich chemoradiotherapy was similarly effective in early-stage ENKTCL compared to sequential chemoradiotherapy, but with higher incidence of grade 3 or 4 hematological AEs [54]. Chemotherapy regimens included in sandwich chemoradiotherapy are LVP (L-asparaginase, vincristine, and prednisone) [55] and MESA (methotrexate, etoposide, dexamethasone, and pegaspargase) [56].…”

Section: Standard Therapy and New Developmentsmentioning

confidence: 99%

EBV-associated NK and T-cell lymphoid neoplasms

Kimura

Leval

Cai

et al. 2022

Current Opinion in Oncology

View full text Add to dashboard Cite

Purpose of reviewEpstein-Barr virus (EBV)-associated neoplasms derived from natural killer (NK) or T cells comprise a group of clinically and biologically heterogenous disorders affecting children and adults, which are overall rare but more prevalent in Asia and South America. This review focuses on neoplasms presenting in the adulthood, addressing recent genomic discoveries as well as therapeutic developments in these highly aggressive disorders. Recent findingsDistinct molecular subtypes of extranodal NK/T-cell lymphomas (ENKTCLs) have been described, with differences in cell of origin, EBV pattern, genomic alterations, clinical characteristics, response to asparaginase-based therapies and to more recent approaches targeting molecular aberrations of the lymphoma. For the last two decades, progress in the clinical management of ENKTCL was based on Lasapraginase containing combinations and the incoroperation of radiotherapy. A subset of cases with PDL1-2 structural alterations may be more responsive to treatment with immune checkpoint inhibitors. Primary nodal EBVþ lymphomas derived from T or NK cells have distinctive features separating them from both peripheral T-cell lymphoma not otherwise specified and ENKTCL. Treatment algorithms correspond to those for advanced ENKTCL.

show abstract

“…With the median radiotherapy dose as 55 Gy, no significant difference is observed in CR, 3‐year OS, or PFS rates between sequential and sandwich groups. Therefore, different types of chemoradiotherapy are effective and safe in the era of L‐saparaginase/pegaspargase in localized NKTCL …”

Section: Treatmentmentioning

confidence: 99%

What we should know about natural killer/T‐cell lymphomas

Xiong

Zhao

2019

Hematological Oncology

View full text Add to dashboard Cite

Natural-killer/T cell lymphoma (NKTCL) is the most common extranodal lymphoma with highly aggressive clinical outcome. System biology techniques provide novel insights into the pathogenesis, risk stratification, and clinical management in NKTCL. Comparative genomic hybridization analysis reveal most frequent deletion of chromosome 6q21. Whole-exome sequencing studies identify recurrent somatic gene mutations, involving RNA helicases, tumor suppressors, JAK-STAT pathway molecules, and epigenetic modifiers. Genome-wide association study reports strongest association of HLA-DPB1 rs9277378 with lymphomagenesis. Alterations of oncogenic signaling pathways as well as epigenetic dysregulation of microRNA and long non-coding RNAs are also observed in NKTCL. Epstein-Barr virus (EBV) is the major etiology of NKTCL and the pathogenic mechanism remains unclear. Different risk stratification models are proposed based on clinical parameters (IPI, PINK, and PINK-E, etc.) or biomarkers (Ki67, C-reactive protein level, and EBV DNA, etc.).Therapeutic strategies vary according to disease stage, including radiotherapy, asparaginase-based chemotherapy, hematopoietic stem-cell transplantation, targeted therapy (immune checkpoints inhibitors, and histone deacetylation inhibitors, etc.).Future investigations will be emphasized on EBV-related pathogenesis of NKTCL, prognostic and therapeutic biomarkers, as well as multi-center clinical trials, so as to optimize personalized treatment of NKTCL in the era of precision medicine.

show abstract

A Multicenter Retrospective Comparison of Sequential versus Sandwich Chemoradiotherapy for Stage IE-IIE Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type

Cited by 12 publications

References 44 publications

NK-/T-cell lymphomas

NK-/T-cell lymphomas

EBV-associated NK and T-cell lymphoid neoplasms

What we should know about natural killer/T‐cell lymphomas

Contact Info

Product

Resources

About